Tuesday December 02 2008 | Biotechnology feed | All feeds
|
|
Tuesday December 02 2008 | Biotechnology feed | All feeds
|
|
|
Inpharmatica announces Chematica(TM) agreement with Novartis
Novartis will use Inpharmatica's
technology to identify protein targets for Novartis' bioactive compounds
London, UK, 13th December 2004 -
Inpharmatica Ltd, the selective drug discovery company, today announced a
discovery collaboration with Novartis Institutes for BioMedical Research, the
pharmaceuticals research organization of Novartis AG (NYSE: NVS).
Under the terms of this agreement, in return for
an undisclosed sum, Novartis Discovery Technologies will use Inpharmatica's
Chematica(TM) technology to identify molecular targets, for Novartis'
bioactive compound project.
Chematica(TM) is the unique chemogenomics
component of PharmaCarta(TM), Inpharmatica's gene to candidate platform, and
seamlessly bridges the gap between biology and chemistry. Chematica(TM) is
capable of target selection through druggability assessment and rapid
identification of hits and leads against those targets.
Commenting on the announcement, Malcolm Weir, Chief Executive Officer of Inpharmatica, said:
"This is a very exciting collaboration for
Inpharmatica. Novartis is a premier drug discovery company and we are proud
that they have chosen our technology to assist in their drug discovery
efforts. We are confident that Chematica(TM) will follow the successful
Biopendium(TM) licensing programme and prove indispensable for drug discovery
for many of the world's significant pharmaceutical and biotechnology
companies."
Inpharmatica: (www.inpharmatica.com)
Founded in 1998, Inpharmatica Ltd is a selective
drug discovery company using predictive technologies to improve speed and
productivity. Focusing on highly druggable targets, its unique proprietary
platform, PharmaCarta(TM), is an integrated suite of informatics-based
technologies fully capable of rapid gene to candidate operations.
Inpharmatica's lead discovery programme is focused on generating pre-clinical
candidates against 16 novel nuclear receptors - proteins widely considered to
be both druggable and of high therapeutic interest. Other significant
programmes include novel secreted proteins/antibody targets, ion channels,
P450 enzymes, metalloproteinases and progestin receptors.
The Company employs approximately 100 professionals at its UK locations in London and Cambridge, with business development headed in North America. Inpharmatica has raised some GBP 49m from leading venture capitalists and has sales/collaboration partnerships with Serono, Pfizer, GSK, Aventis, Daiichi, Riken, Taisho, Chugai, MDL, Ionix, CellZome and Galapagos. Inpharmatica's Chematica(TM) technology is endorsed by Procter & Gamble who signed a collaboration agreement in May 2004. Andrew Lloyd & Associates |
|
|
